At a time when patients are increasingly turning to social media such as Facebook for information about medical conditions and their treatment, a new study raises disturbing questions about the accuracy of the information on these sites….

Research on insulin-sensitizers can pave the way to identifying a novel therapeutic strategy for the management of prostatic enlargement in insulin-resistant individuals….

Beginning dialysis therapy earlier in the development of advanced kidney disease appears to be associated with a greater risk of death for some patients in the following year, according to a report….

Vitamins and supplements in the U.S. are big business: half of all Americans routinely take them at the rate of about $23 billion dollars every year….

A narrow threshold range for diabetes-specific retinopathy was identified for FPG and HbA1c….

Relationships with drug manufacturers, device companies and other medical companies appear to have decreased since 2004 but remain common among physicians, according to a new report in JAMA….

When I received this week’s Diabetes Clinical Mastery Series’ articles and contents from our staff, I’d just finished seeing patients. It had been a frustrating day: I had spent considerable time trying to explain why diabetes has so many complications to one patient; teaching another patient who had lost their …

The slides in this section provide an overview of the classification, etiology, and diagnostic criteria for Type 1 and Type 2 diabetes.

The elections are over and the voters have spoken … or have they? I thought that most of the dissatisfaction with what has been happening the past three to four years has been about the economy. Isn’t that why we had a change in leadership two years ago and isn’t …

KOMBIGLYZE™ XR (Saxagliptin and Metformin HCl Extended-Release) tablets approved in the U.S. for the treatment of Type 2 diabetes mellitus in adults — the first and only once-a-day metformin extended-release (XR) plus DPP-4 inhibitor combination tablet. FDA Rejects Another New Diabetes Drug – Linjeta, a new rapid acting insulin. FDA …